Ironwood plans sale of 33,000 common shares

Ironwood Pharmaceuticals filed to sell common stock through Morgan Stanley Smith Barney LLC.

Rhea-AI Filing Summary

Ironwood Pharmaceuticals filed to sell common stock through Morgan Stanley Smith Barney LLC. The filing covers 33,000 shares of common stock with an aggregate market value of $2,527,470.00, expected to be sold on July 13, 2026 on NASDAQ. The shares are tied to an exercise of stock options for cash. The disclosure also notes prior Rule 10b5-1 sales for John Quisel of 34,000 shares of common stock on June 18, 2026 for proceeds of $2,387,296.40.

Filing Explained

The July 13 filing is a planned, cash-funded option exercise and 33,000-share sale by John Quisel, not evidence that the sale has occurred.

The July 13, 2026 Form 144 reports a proposed sale of 33,000 common shares associated with John Quisel, following a cash exercise of stock options; it does not report that this sale has occurred.

The filing labels the transaction as a 10b5-1 sale, which refers to a written trading plan adopted in advance that executes trades on a schedule or formula.

It also lists 34,000 common shares sold on June 18, 2026 as 10b5-1 sales.

At this stage, the disclosure describes a planned filer transaction and its option-exercise mechanics, but it does not establish a completed sale or a resulting change in the issuer's shares outstanding.

Key Figures

Shares planned for sale: 33,000 shares Aggregate market value: $2,527,470.00 Prior 10b5-1 sale shares: 34,000 shares +2 more

5 metrics

Shares planned for sale 33,000 shares Common stock to be sold on or about July 13, 2026

Aggregate market value $2,527,470.00 Market value of 33,000 common shares covered by the filing

Prior 10b5-1 sale shares 34,000 shares Common shares sold on June 18, 2026 under 10b5-1 sales for John Quisel

Prior 10b5-1 sale value $2,387,296.40 Proceeds from 34,000-share Rule 10b5-1 sale on June 18, 2026

Planned sale date 07/13/2026 Intended date for sale of 33,000 common shares

Key Terms

Form 144, Exercise of Stock Options, 10b5-1

3 terms

Form 144 regulatory

"144: Securities Information Common | Morgan Stanley Smith Barney LLC"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Exercise of Stock Options financial

"Common | 07/13/2026 | Exercise of Stock Options | Issuer"

10b5-1 regulatory

"10b5-1 Sales for JOHN QUISEL 321 Arsenal Street"

A 10b5-1 plan is a pre-set schedule that lets company insiders buy or sell shares according to written instructions made when they do not possess material, nonpublic information. Think of it as a timed automatic payment for stock trades: it helps insiders avoid accusations of trading on secret information and gives outside investors a clearer signal about whether sales are routine or potentially informative about the company’s prospects.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock sale is disclosed for IRON in this Form 144?

The filing covers a planned sale of 33,000 shares of Ironwood Pharmaceuticals common stock, with an aggregate market value of $2,527,470.00, expected to be sold on July 13, 2026 on NASDAQ.

What is the source of the IRON shares to be sold on July 13, 2026?

The 33,000 shares of Ironwood Pharmaceuticals common stock are associated with an exercise of stock options, with the transaction structured for cash settlement on July 13, 2026.

Which broker is handling the planned IRON stock sale?

The planned sale of 33,000 shares of Ironwood Pharmaceuticals common stock is to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services, based at 1 New York Plaza, New York, NY 10004.

What recent Rule 10b5-1 sales are reported for IRON?

The filing notes Rule 10b5-1 sales for John Quisel of 34,000 shares of Ironwood Pharmaceuticals common stock on June 18, 2026, with total proceeds of $2,387,296.40 from those sales.

On which exchange will the IRON shares be sold under this Form 144?

The 33,000 shares of Ironwood Pharmaceuticals common stock covered by the filing are expected to be sold on the NASDAQ market on or about July 13, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/13/2026 - 04:34 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001586788
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Disc Medicine, Inc.
SEC File Number	001-39438
Address of Issuer	321 Arsenal Street, Suite 101 Watertown MASSACHUSETTS 02472
Phone	6176749274
Name of Person for Whose Account the Securities are To Be Sold	JOHN QUISEL
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	33000	2527470.00	38199089	07/13/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	07/13/2026	Exercise of Stock Options	Issuer			33000	07/13/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for JOHN QUISEL 321 Arsenal Street, Suite 101 Watertown MA 02472	Common	06/18/2026	34000	2387296.40

144: Remarks and Signature

Remarks
Date of Notice	07/13/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	03/12/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ John Quisel
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)